Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients

被引：23

作者：

Yu, Dianke ^{[2
,3
]}

Shi, Juan ^{[4
]}

Sun, Tong ^{[5
,6
]}

Du, Xiaoli ^{[7
]}

Liu, Li ^{[4
]}

Zhang, Xiaojiao ^{[4
]}

Lu, Chao ^{[4
]}

Tang, Xiaohu ^{[4
]}

Li, Meng ^{[4
]}

Xiao, Lingchen ^{[4
]}

Zhang, Zhouwei ^{[4
]}

Yuan, Qipeng ^{[1
,4
]}

Yang, Ming ^{[1
,4
]}

机构：

[1] Beijing Univ Chem Technol, Coll Life Sci & Technol, Beijing 100029, Peoples R China

[2] Chinese Acad Med Sci, State Key Lab Mol Oncol, Dept Etiol & Carcinogenesis, Canc Inst & Hosp, Beijing 100730, Peoples R China

[3] Peking Union Med Coll, Beijing 100021, Peoples R China

[4] Beijing Univ Chem Technol, Coll Life Sci & Technol, Beijing, Peoples R China

[5] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[6] Harvard Univ, Sch Med, Boston, MA USA

[7] NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA

来源：

TUMOR BIOLOGY | 2012年 / 33卷 / 03期

基金：

中国国家自然科学基金;

关键词：

Chemotherapy; ERCC1; Meta-analysis; Pharmacogenetics; Platinum; NUCLEOTIDE EXCISION-REPAIR; DNA-REPAIR; POLYMORPHISMS; CISPLATIN; SURVIVAL; XPD; ENDONUCLEASE; METAANALYSIS; ASSOCIATION; EXPRESSION;

D O I：

10.1007/s13277-011-0314-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The excision repair cross-complementation group 1 (ERCC1) plays an essential role in DNA repair and has been linked to resistance to platinum-based anticancer drugs among advanced non-small cell lung cancer (NSCLC) patients. We systematically evaluate whether ERCC1 Asn118Asn and C8092A genetic variants are associated with treatment response of platinum chemotherapy. We preformed a meta-analysis using ten eligible cohort studies (including 11 data-sets) with a total of 1,252 NSCLC patients to summarize the existing data on the association between the ERCC1 Asn118Asn and C8092A polymorphisms and response to platinum regiments. Odds ratio or hazard ratio with 95% confidence interval were calculated to estimate the correlation. We found that neither ERCC1 C8092A polymorphism nor Asn118Asn variant is associated with different response of platinum-based treatment among advanced NSCLC patients. Additionally, these two genetic variants are not related to treatment response in either Caucasian patients or Asian patients. Our meta-analysis indicates that the ERCC1 Asn118Asn and C8092A polymorphisms may not be good prognostic biomarkers for platinum-based chemotherapy in patients with stage III-IV NSCLC.

引用

页码：877 / 884

页数：8

共 50 条

[21] Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T Predict Outcome of Platinum-based Chemotherapies in Advanced Non-small Cell Lung Cancer: A Meta-analysis [J].

Wei, Hai-bo ;

Lu, Xiang-shi ;

Shang, Li-hua ;

Xu, Gang ;

Hu, Jing ;

Che, De-hai ;

Liu, Fang ;

Wu, Ying ;

Zhang, Guang-mei ;

Yu, Yan .

ARCHIVES OF MEDICAL RESEARCH, 2011, 42 (05) :412-420

[22] Genome-wide examination of genetic variants associated with response to platinum-based chemotherapy in patients with small-cell lung cancer [J].

Wu, Chen ;

Xu, Binghe ;

Yuan, Peng ;

Ott, Jurg ;

Guan, Yin ;

Liu, Yu ;

Liu, Zhe ;

Shen, Yuanyuan ;

Yu, Dianke ;

Lin, Dongxin .

PHARMACOGENETICS AND GENOMICS, 2010, 20 (06) :389-395

[23] Predictive Role of ERCC1 and XPD Genetic Polymorphisms in Survival of Chinese Non-small Cell Lung Cancer Patients Receiving Chemotherapy [J].

Zhang, Zhen-Yong ;

Tian, Xin ;

Wu, Rong ;

Liang, Yuan ;

Jin, Xue-Ying .

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (06) :2583-2586

[24] ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy [J].

Wang, Xiyong ;

Zhu, Xiaoli ;

Zhang, Hongming ;

Fan, Xiaobo ;

Xue, Xiulei ;

Chen, Yan ;

Ding, Chenbo ;

Zhao, Jianwen ;

Wu, Guoqiu .

JOURNAL OF CANCER, 2017, 8 (14) :2846-2853

[25] Effect of ERCC1 polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer [J].

Gao, H. ;

Ge, R. C. ;

Liu, H. Y. ;

Wang, Y. ;

Yan, S. .

GENETICS AND MOLECULAR RESEARCH, 2014, 13 (04) :8997-9004

[26] Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis [J].

Shu-zhen Wei ;

Ping Zhan ;

Mei-qi Shi ;

Yi Shi ;

Qian Qian ;

Li-ke Yu ;

Yong Song .

Medical Oncology, 2011, 28 :315-321

[27] Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer [J].

Wang, Xin ;

Zhao, Jun ;

Yang, Lu ;

Mao, Li ;

An, Tongtong ;

Bai, Hua ;

Wang, Shuhang ;

Liu, Xuyi ;

Feng, Guoshuang ;

Wang, Jie .

MEDICAL ONCOLOGY, 2010, 27 (02) :484-490

[28] Variants of ERCC5 and the outcome of platinum-based regimens in non-small cell lung cancer: a prospective cohort study [J].

Abdalkhalek, Esraa S. ;

El Wakeel, Lamia M. ;

Nagy, Ahmed A. ;

Sabri, Nagwa A. .

MEDICAL ONCOLOGY, 2022, 39 (10)

[29] ERCC1 as a marker of prognosis and sensitivity to platinum-based chemotherapy in patients with stage III-IV non-small cell lung cancer [J].

Kolesnik, O. P. ;

Kuzmenko, V. O. .

PATHOLOGIA, 2020, (01) :15-20

[30] Expression of ERCC1 and BRCA1 predict the clinical outcome of non-small cell lung cancer in patients receiving platinum-based chemotherapy [J].

Wang, T. B. ;

Zhang, N. L. ;

Wang, S. H. ;

Li, H. Y. ;

Chen, S. W. ;

Zheng, Y. G. .

GENETICS AND MOLECULAR RESEARCH, 2014, 13 (02) :3704-3710

← 1 2 3 4 5 →